order
combat
infecti
diseas
number
import
discoveri
invent
antibiot
vaccin
chemotherapeut
drug
made
despit
signific
progress
infecti
diseas
still
largest
caus
death
world
epidem
caus
emerg
reemerg
infecti
organ
seriou
threat
human
health
heeney
consid
recent
exampl
gener
spread
sever
acut
respiratori
syndrom
sar
viru
west
nile
viru
wnv
avian
influenza
viru
infecti
diseas
spread
quickli
increas
global
travel
export
import
anim
may
harbor
virus
tapper
world
unprepar
real
threat
natur
occur
outbreak
intent
viru
releas
deadli
bioweapon
combat
emerg
virus
well
drugresist
mutant
virus
effect
treatment
exist
continu
increas
vigil
requir
includ
develop
new
broadspectrum
therapi
vaccin
princip
defens
viral
infect
plotkin
use
negat
util
antivir
drug
great
need
develop
compound
therapeut
efficaci
treat
diseas
caus
highli
pathogen
rna
virus
bray
treatment
influenzatyp
ill
inhibitor
amantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
exist
therapeut
drug
howev
except
ribavirin
approv
drug
avail
rna
viru
infect
especi
true
sever
type
viral
hemorrhag
fever
gowen
holbrook
applic
ribavirin
treatment
sever
infect
becom
widespread
concern
regard
advers
effect
lack
specif
efficaci
kilgor
et
al
mccormick
et
al
monath
articl
provid
overview
antivir
activ
favipiravir
relat
pyrazinecarboxamid
compound
sever
rna
virus
potenti
novel
antivir
drug
treatment
emerg
pathogen
rna
viru
infect
discov
synthes
toyama
chemic
co
ltd
structur
shown
fig
screen
chemic
librari
toyama
chemic
co
ltd
use
plaqu
reduct
assay
antivir
activ
influenza
viru
lead
compound
afterward
design
found
effect
thereaft
deriv
synthes
evalu
structureact
studi
term
vitro
vivo
antivir
activ
well
pharmacokinet
properti
relat
compound
select
investig
drug
candid
influenza
viru
member
orthomyxovirida
famili
three
type
b
c
known
exist
type
influenza
viru
classifi
mani
subtyp
accord
differ
surfac
antigen
human
usual
infect
three
type
b
type
epidem
repeat
yearli
frequent
mutat
viru
retrospect
studi
report
pandem
influenza
outbreak
recur
cycl
year
due
antigen
shift
glezen
webbi
webster
influenza
viru
infect
upper
airway
patient
usual
develop
fever
suffer
fatigu
day
follow
full
recoveri
approxim
week
howev
sever
ill
seen
newborn
elderli
patient
chronic
ill
cardiac
disord
pulmonari
diseas
diabet
immunodefici
furthermor
sever
complic
includ
death
occur
recent
outbreak
highli
pathogen
avian
influenza
occur
southeast
asia
kay
pringl
abdelghafar
et
al
high
mortal
rate
human
report
author
fear
avian
flu
acquir
abil
transmit
human
human
touch
pandem
could
kill
million
peopl
antiinfluenza
activ
evalu
plaqu
reduct
assay
influenza
b
c
virus
furuta
et
al
inhibit
plaqu
format
type
laboratoryadapt
clinic
isol
influenza
virus
low
ec
valu
tabl
antivir
activ
influenza
viru
well
oseltamivirresist
viru
determin
yield
reduct
assay
mdck
cell
furuta
et
al
ec
valu
effect
influenza
rang
similar
effect
concentr
season
influenza
virus
oseltamivir
show
antiinfluenza
viral
activ
low
concentr
except
c
type
oseltamivirresist
strain
ribavirin
also
show
activ
potenc
time
less
effect
depend
strain
vivo
therapeut
efficaci
evalu
use
balbc
mice
infect
influenza
virus
furuta
et
al
sidwel
et
al
one
exampl
mice
infect
intranas
lethal
dose
influenza
viru
oseltamivir
administ
oral
day
begin
h
postinfect
oral
treatment
dose
mgkgday
prevent
death
inhibit
lung
consolid
reduc
lung
viru
titer
tabl
import
desir
characterist
antivir
drug
effect
even
treatment
begun
viral
infect
establish
clinic
symptom
appear
result
studi
delay
initi
treatment
use
influenza
strain
show
mark
reduct
mortal
even
treatment
initi
h
post
nt
test
antivir
activ
determin
plaqu
reduct
assay
furuta
et
al
b
antivir
activ
determin
yield
reduct
assay
furuta
et
al
expt
effect
drug
dose
surviv
mice
treat
twice
daili
cmc
vehicl
day
begin
h
viru
exposur
expt
effect
delay
initi
treatment
mice
treat
cmc
vehicl
everi
h
day
begin
indic
hour
postinfect
sd
standard
deviat
p
p
compar
control
treat
cmc
viru
infect
significantli
highli
effect
recent
emerg
highli
virul
viru
tabl
mice
treat
also
display
significantli
reduc
declin
arteri
oxygen
satur
sao
infect
model
compar
experi
oseltamivir
use
mice
infect
high
challeng
dose
influenza
viru
complet
prevent
death
surviv
rate
significantli
higher
oseltamivirtr
anim
takahashi
et
al
timeofaddit
experi
reveal
inhibit
earli
middl
stage
influenza
viral
replic
hamster
oral
treat
ribavirin
twice
daili
day
begin
h
previru
inocul
viral
titer
determin
day
infect
express
cell
cultur
infecti
g
liver
ml
serum
percentag
anim
present
detect
viru
level
indic
parenthesi
alt
alanin
aminotransferas
intern
unit
per
liter
sd
standard
deviat
p
p
p
compar
control
treat
cmc
vehicl
gowen
et
al
adsorpt
releas
stage
vitro
antivir
activ
attenu
purin
purin
nucleosid
pyrimidin
ad
cultur
phenomenon
suggest
act
purin
purin
nucleosid
viral
rna
replic
furuta
et
al
experi
use
c
radiolabel
triphosph
monophosph
detect
cultur
mdck
cell
furthermor
found
inhibit
influenza
viru
rna
polymeras
activ
dosedepend
manner
gtpcompetit
manner
k
inhibitori
potenc
approxim
time
higher
ribavirin
triphosph
hand
inhibit
viral
rnadepend
rna
polymeras
inhibit
cellular
inosin
monophosph
dehydrogenas
impdh
metabolit
weaker
ribavirin
monophosph
furuta
et
al
summari
experiment
observ
mechan
action
antiinfluenza
drug
illustr
fig
differ
mechan
action
approv
antiinfluenza
viru
drug
viru
select
favor
featur
distinguish
ribavirin
sever
diseas
high
mortal
rate
associ
infect
caus
agent
viral
hemorrhag
fever
vhf
virus
caus
diseas
among
fear
vhf
agent
belong
arenavirida
bunyavirida
filovirida
flavivirida
rna
viru
famili
current
pauciti
safe
effect
antivir
drug
treatment
vhf
limit
number
studi
human
primat
ribavirin
proven
effect
sever
arenavir
bunyavir
hemorrhag
fever
enria
maiztegui
ergonul
ergonul
et
al
kilgor
et
al
mardani
et
al
mccormick
et
al
concern
doserel
hemolyt
anemia
potenti
teratogen
approv
compassion
use
investig
new
drug
protocol
borio
et
al
threat
intent
releas
hemorrhag
fever
agent
bioweapon
increas
frequenc
natur
occur
outbreak
stress
need
develop
novel
therapeut
diseas
manag
strategi
shown
highli
activ
sever
bunyaviru
la
cross
punta
toro
rift
valley
fever
sandfli
fever
arenaviru
junin
pichind
tacarib
cell
cultur
system
measur
inhibit
cytopath
effect
viru
yield
reduct
gowen
et
al
ec
valu
rang
bunyavirus
arenavirus
examin
respect
robust
therapeut
indic
si
gowen
et
al
ec
ribavirin
test
panel
bunyavirus
arenavirus
gowen
et
al
thu
vitro
activ
compar
superior
ribavirin
si
valu
higher
vivo
efficaci
evalu
punta
toro
viru
ptv
infect
mous
hamster
model
rift
valley
fever
gowen
et
al
robust
protect
highli
lethal
ptv
challeng
seen
mice
hamster
administ
h
prior
h
viru
inocul
dose
given
twice
daili
day
suffici
efficaci
treatment
initi
h
challeng
mice
treatment
begin
day
viru
inocul
also
effect
although
higher
dose
mgkgday
need
ribavirin
hamster
oral
treat
ribavirin
twice
daili
day
begin
h
previru
inocul
viral
titer
serum
alanin
aminotransferas
alt
level
determin
day
postinfect
five
anim
per
group
mdd
mean
day
death
viral
titer
cell
cultur
infecti
g
liver
ml
serum
percentag
anim
present
detect
viru
level
indic
parenthesi
alt
intern
unit
per
liter
sd
standard
deviat
p
p
p
compar
control
treat
cmc
vehicl
gowen
et
al
surviv
pichind
virusinfect
hamster
treat
placebo
begin
day
postinfect
given
twice
daili
mgkgday
first
day
mgkgday
thereaft
p
compar
respect
placebotr
hamster
logrank
test
gowen
et
al
gowen
et
al
hamster
slightli
higher
dose
mgkgday
requir
obtain
optim
efficaci
start
treatment
h
preinfect
tabl
hamster
consider
suscept
ptv
gowen
holbrook
gowen
et
al
gener
difficult
treat
anim
studi
examin
activ
authent
highli
pathogen
strain
rift
valley
fever
need
pichind
viru
picv
hamster
infect
model
arenavir
hemorrhag
fever
prophylact
therapeut
treatment
yield
dramat
protect
gowen
et
al
initi
studi
picvinfect
hamster
establish
effect
daili
dose
mgkgday
twicedaili
treatment
initi
within
h
infect
tabl
treatment
begun
day
challeng
dose
mgkgday
effect
suggest
higher
dose
need
effect
control
infect
gowen
et
al
recent
signific
protect
achiev
employ
highdos
regimen
load
dose
use
knock
mark
viral
burden
present
treatment
delay
day
twicedaili
dose
mgkg
given
either
day
follow
day
twicedaili
dose
mgkg
fig
notabl
picvinfect
hamster
normal
begin
succumb
day
infect
peak
serum
tissu
viral
burden
present
anim
day
underscor
signific
find
regard
toxic
ld
hamster
six
time
higher
ribavirin
suggest
superior
ribavirin
perspect
safeti
result
support
assumpt
may
viabl
altern
treatment
lifethreaten
bunyavir
arenavir
infect
experi
investig
activ
lassa
fever
viru
south
american
hemorrhag
fever
virus
underway
yfv
member
flavivirida
famili
arbovirus
respons
mani
outbreak
hemorrhag
diseas
mani
countri
africa
south
america
caus
estim
death
year
despit
avail
effect
vaccin
tomori
advers
vaccin
event
import
yfv
unvaccin
travel
document
outsid
area
endemn
approv
antivir
treatment
yfv
monath
therefor
develop
therapeut
agent
treatment
yfv
import
especi
effect
onset
clinic
symptom
vitro
cytopath
effect
reduct
assay
vero
cell
show
weak
activ
yfv
ec
fig
surviv
yfvinfect
hamster
treat
ip
mgkgday
start
variou
time
viru
challeng
beg
begin
treatment
p
p
compar
placebotr
anim
juland
et
al
valu
respect
juland
et
al
juland
et
al
howev
despit
vitro
result
show
surpris
therapeut
efficaci
hamster
model
yf
juland
et
al
intraperiton
treatment
dose
mgkgday
begin
h
viru
inocul
continu
twice
daili
day
result
lower
alt
ast
level
serum
less
weight
loss
significantli
improv
surviv
also
effect
administ
oral
minim
effect
dose
mgkgday
similar
intraperiton
treatment
surviv
rate
significantli
improv
even
hamster
treat
mgkgday
twice
daili
begin
late
day
postinfect
fig
comparison
ribavirin
dose
mgkgday
significantli
improv
surviv
rate
alt
level
infect
hamster
given
h
prior
viru
challeng
hand
dose
mgkgday
requir
achiev
result
similar
obtain
treatment
tabl
juland
et
al
protect
mortal
also
observ
hamster
treat
mgkgday
insuffici
data
clarifi
reason
vivo
antivir
effect
correspond
vitro
activ
differ
antivir
activ
possibl
explan
convers
rate
activ
form
hamster
liver
higher
cultur
cell
furuta
et
al
case
expect
use
drug
yf
human
like
yfv
dengu
viru
japanes
enceph
viru
wnv
mosquitoborn
member
flavivirida
famili
wnv
first
tabl
effect
treatment
viru
exposur
hamster
challeng
yfv
time
start
therapi
h
survivorstot
mdd
sd
serum
alt
sd
ribavirin
oral
administ
twice
daili
day
dose
mgkgday
ribavilrin
administ
dose
mgkgday
mdd
mean
day
death
sd
standard
deviat
alt
serum
alanin
aminotransferas
intern
unit
per
liter
p
p
p
compar
salinetr
control
juland
et
al
isol
patient
west
nile
district
uganda
sinc
viru
isol
variou
region
world
spread
north
america
hay
shown
viru
could
spread
whole
world
effect
vaccin
develop
countermeasur
requir
vitro
antivir
activ
evalu
vero
cell
new
york
isol
wnv
ec
valu
vivo
efficaci
studi
mice
golden
syrian
hamster
use
mice
hamster
infect
subcutan
wnv
new
york
strain
administ
oral
twice
daili
begin
h
infect
day
oral
administ
mgkgday
protect
mice
wnvinduc
mortal
reduc
viral
rna
level
brain
spleen
without
reduct
bodi
weight
treatment
could
delay
day
challeng
still
achiev
efficaci
mice
fig
minim
effect
oral
dose
administ
twice
day
begin
day
viral
challeng
mgkgday
mice
mgkgday
dose
regimen
also
significantli
improv
surviv
hamster
notabl
immunohistochem
detect
wnv
envelop
protein
observ
brain
treat
hamster
although
seen
placebotr
anim
fig
investig
consid
treatment
wnv
one
compound
known
reduc
wnvinduc
mortal
rodent
footandmouth
diseas
fmd
highli
contagi
econom
devast
diseas
clovenhoof
anim
includ
swine
bovin
caus
agent
fmdv
aphthoviru
picornavirida
famili
caus
rapidli
spread
acut
infect
character
fever
lame
vesicular
lesion
feet
tongu
snout
teat
grubman
baxt
region
fmd
enzoot
diseas
control
achiev
two
polici
test
slaughter
andor
vaccin
fmd
outbreak
occur
countri
use
either
approach
depend
epidemiolog
situat
recent
outbreak
occur
taiwan
dunn
donaldson
uk
gibben
et
al
caus
seriou
econom
damag
rate
fmd
transmiss
depend
sever
factor
among
infect
speci
breed
virul
fmdv
strain
rout
infect
environ
differ
immun
statu
individu
anim
qualiti
fmd
vaccin
gener
take
day
vaccin
elicit
protect
antibodi
doel
compens
disadvantag
fmd
vaccin
new
control
method
exhibit
prompt
effect
must
develop
therefor
antivir
agent
one
sever
power
tool
reduc
expans
fmd
break
thu
provid
addit
mean
control
spread
diseas
vitro
antifmdv
activ
assess
plaqu
reduct
assay
strain
show
potent
antivir
activ
ec
valu
administ
feed
four
pig
dose
mgkg
twice
daili
day
begin
h
prior
fmdv
inocul
sakamoto
et
al
anim
control
group
show
typic
sign
fmd
fever
vesicl
feet
lame
clinic
sign
fmd
observ
pig
throughout
experi
viremia
effect
reduc
level
detect
increas
antifmd
antibodi
titer
suppress
treatment
suggest
viru
replic
effect
inhibit
compound
infect
pig
also
note
viru
detect
nasal
swab
anim
inhibit
viru
secret
import
factor
treatment
pig
infect
fmdv
given
pig
known
import
amplifi
host
excret
approxim
time
viru
host
cattl
sinc
compound
administ
food
larg
number
anim
treat
rel
littl
effort
thu
could
power
tool
control
fmd
pig
alphavirus
venezuelan
equin
enceph
viru
veev
western
equin
enceph
viru
weev
also
inhibit
cell
cultur
si
compar
seen
flavivirus
effect
vivo
howev
less
seen
flavivirus
treatment
dose
mgkgday
result
modest
signific
improv
surviv
mous
model
weev
juland
show
activ
either
veev
weev
rna
virus
includ
polioviru
rhinoviru
respiratori
syncyti
viru
rsv
also
shown
suscept
ec
gml
respect
furuta
et
al
howev
ec
valu
gml
show
effect
plaqu
format
herp
simplex
viru
type
human
cytomegaloviru
hcmv
adenoviru
hand
ribavirin
shown
inhibit
growth
dna
virus
allen
et
al
markland
et
al
addit
activ
seen
yfv
also
activ
bovin
viral
diarrhea
viru
bvdv
anoth
flaviviru
well
hepat
c
viru
hcv
furuta
et
al
reduc
bvdv
replic
mdbk
cell
ec
valu
yield
reduct
assay
similar
activ
observ
inhibit
bvdv
cell
cultur
ec
show
less
activ
ec
addit
phosphoryl
observ
sever
mammalian
cell
liver
anim
treat
compound
triphosph
also
found
inhibit
viral
rna
polymeras
hcv
enzym
assay
furuta
et
al
investig
therapeut
efficaci
hcv
warrant
appropri
anim
model
studi
pyrazinecarboxamid
deriv
includ
found
possess
favor
antivir
activ
rna
virus
show
therapeut
effect
number
anim
model
regard
mechan
action
experiment
find
suggest
convert
ribofuranosyltriphosph
deriv
host
cellular
enzym
metabolit
inhibit
viral
rnadepend
rna
polymeras
noteworthi
inhibit
viral
replic
without
influenc
synthesi
cellular
dna
rna
furuta
et
al
high
error
rate
rna
polymeras
consid
one
strategi
execut
rna
virus
escap
host
immun
respons
fals
recognit
nucleotid
viral
polymeras
might
occur
frequent
compar
host
rna
polymeras
day
et
al
leyssen
et
al
although
consider
evid
support
inhibit
influenza
polymeras
fulli
understood
activ
form
inhibit
rnadepend
rna
polymeras
exampl
follow
question
remain
clarifi
suppress
enzym
function
bind
enzym
molecul
incorpor
nascent
viral
rna
replic
process
suppress
translat
viral
protein
viral
mutagen
like
ribavirin
addit
tri
obtain
strain
serial
passag
influenza
resist
virus
could
isol
passag
unpublish
data
although
inabl
develop
drug
resist
clearli
advantag
make
analyz
mechan
action
molecular
level
difficult
hand
observ
antivir
activ
pyrazinecarboxamid
deriv
vari
larg
depend
kind
host
cell
use
exampl
antivir
activ
influenza
higher
mdck
cell
antivir
potenc
revers
mdbk
cell
unpublish
data
sinc
presum
compound
convert
activ
ribofuranosyltriphosph
form
cellular
enzym
antivir
activ
would
greatli
affect
uptak
parent
compound
host
cell
andor
convers
rate
activ
form
import
point
consid
estim
therapeut
efficaci
compound
variou
viral
diseas
variat
distribut
convers
compound
target
organ
cell
could
caus
differ
antivir
spectrum
clinic
phase
iii
trial
influenza
usa
japan
nonclin
clinic
data
toxicolog
pharmacokinet
accumul
exampl
nonclin
pharmacokinet
studi
reveal
plasma
level
oral
administr
rose
dosedepend
manner
high
linear
oral
bioavail
mice
almost
compar
intraven
administr
addit
seriou
advers
event
report
clinic
studi
suggest
well
toler
human
data
help
us
consid
possibl
novel
antivir
drug
variou
rna
viral
infect
first
indic
influenza
develop
plan
hereaft
necessari
also
consid
diseas
caus
medic
import
virus
lassa
junin
wnv
yfv
regard
develop
elucid
effect
power
tool
control
fmd
pig
largescal
experi
expect
use
infect
model
fmdv
conclus
pyrazinecarboxamid
deriv
appear
promis
tool
satisfi
unmet
need
treat
highli
pathogen
rna
viral
infect
virolog
branch
niaid
nih
